State Failure To Re-Test Sub-Standard Drugs Invalidates Blacklisting Order: SC
Copy Link
Share
Save
The Supreme Court has flagged that State negligence in facilitating re-testing of disputed drug samples before their expiry permanently deprives suppliers of their statutory defence, rendering subsequent blacklisting actions illegal. The Bench has ruled that procedural non-compliance combined with state-caused delays that frustrate a party's right to independent laboratory testing invalidates administrative debarment.
A three-judge bench comprising Justice Vikram Nath, Justice Augustine George Masih, and Justice Sandeep Mehta set aside orders of the Madhya Pradesh authorities blacklisting a drug manufacturing firm. The Apex Court underscored that administrative entities cannot enforce punitive debarment based on contested laboratory reports when mandatory re-testing procedures under tender conditions and statutory provisions are denied.
Key Takeaways
- Mandatory Second Sample Testing: Procuring authorities must strictly adhere to tender clauses requiring a second laboratory analysis before imposing blacklisting orders for quality failures.
- Prejudiced Statutory Safeguards: State-caused delays resulting in drug shelf-life expiry permanently extinguish the supplier's right to controvert lab reports under Section 25 of Drugs and Cosmetics Act, 1940.
- Contingent Debarment Orders Invalid: High Courts cannot keep illegal blacklisting orders alive by making their survival contingent on delayed re-testing outcomes.
- Civil Consequences Demand Rigorous Due Process: Punitive actions like blacklisting carry severe civil consequences and cannot be sustained on flawed procedural foundations.
Statutory Safeguards and Re-Testing of Drug Samples
The Supreme Court observed that the authorities passed blacklisting orders in haste without complying with Clause 6 of Annexure IX of the Tender Document, which mandatorily required drawing a second sample from the same batch for testing at another laboratory. The Bench emphasised that delay predominantly attributable to the State which results in the loss of an effective opportunity to have a sample retested renders punitive action unsustainable. Highlighting the legal principle, the Supreme Court referred to Medipol Pharmaceutical India Pvt. Ltd. v. Post Graduate Institute of Medical Education & Research ( "(2021) 11 SCC 339": 2020 CaseBase(SC) 288), which had relied on Medicamen Biotech Ltd. v. Rubina Bose, Drug Inspector ( "(2008) 7 SCC 196": 2008 CaseBase(SC) 2104) and Laborate Pharmaceuticals India Ltd. v. State of Tamil Nadu, to reinforce the necessity of preserving a supplier's right to appellate laboratory testing under Section 25(3) and (4) of Drugs and Cosmetics Act, 1940.
The Bench reasoned to observe that “The failure to follow the procedure expressly stipulated in Clause 6, followed by the non-compliance with the High Court’s direction for re-testing within the stipulated period, has deprived the appellant-firm of an effective opportunity to challenge the very reports forming the foundation of the impugned action. The subsequent expiry of the batches has rendered that opportunity nugatory. In these circumstances, the respondents cannot be permitted to sustain the impugned punitive action on the strength of reports which the appellant-firm was denied an effective opportunity to controvert despite its entitlement under the Tender document.”
Ratio
Where an administrative or penal action of blacklisting is founded upon an adverse test report of a perishable commodity, the failure of the State or procuring entity to adhere to mandatory re-testing procedures, coupled with state-attributable delay resulting in the expiry of the sample's shelf-life, irretrievably deprives the party of its valuable right to controvert the report, rendering the resulting order of blacklisting void and unsustainable in law.
Background
The appellant firm entered into an agreement with the M.P. Public Health Services Corporation Limited (MPPHSCL) for supplying Ascorbic Acid (Vitamin C) Tablets and Ethambutol Hydrochloride Tablets to district hospitals. Following a show-cause notice alleging four batches had failed quality tests and were declared Not of Standard Quality (NSQ), the Managing Director of MPPHSCL issued orders on September 30, 2024, debarring the firm's product for two years and blacklisting the firm for three years, alongside demanding recovery of the batch values.
Although the firm submitted its reply within the allotted time denying the allegations and citing improper storage conditions, the authorities failed to follow Clause 6 of Annexure IX of the Tender Document, which prescribed drawing a second sample for independent testing prior to blacklisting. Upon writ proceedings, the High Court of Madhya Pradesh directed fresh samples to be drawn and tested at a Central Government Laboratory within 15 days but made the quashing of blacklisting contingent upon the re-test results.
Due to inter-departmental inaction, the re-testing was delayed for over six months, during which time all concerned drug batches reached their expiry dates. Challenging the High Court's refusal to unconditionally quash the blacklisting orders, the supplier appealed to the Supreme Court. The Supreme Court allowed the appeals and set aside the debarment orders.
Case Details:
Case No.: Civil Appeal No(s). OF 2026 (Arising out of SLP (Civil) No (s). 14499-14500 of 2026)
Neutral Citation: 2026 INSC 1143
Case Title: M/S JPEE DRUGS v. STATE OF MADHYA PRADESH AND OTHERS
Appearances:
For the Petitioner(s): Shri Siddharth Bhatnagar, Senior Counsel
For the Respondent(s): Shri S.K. Gangele, Senior Counsel
Source: 2026 CaseBase(SC) 9490
Similar Articles
Breaking News
